Monami, Matteo, Silverii, Antonio, Miranda, Cesare, Monge, Luca, Uccioli, Luigi, Scevola, Germano, Stabile, Eugenio, Gargiulo, Mauro, Scatena, Alessia, Ragghianti, Benedetta, Vermigli, Cristiana, Bernetti, Andrea, Bordieri, Corrado, Cappella, Cristina, De Cassai, Alessandro, Falcone, Marco, Lorenzoni, Valentina, Medea, Gerardo, Stefanon, Laura, and Tramonta, Rodolfo
This article is a meta-analysis of randomized clinical trials on the use of prostanoids in patients with diabetes and chronic limb-threatening ischemia (CLTI) for the treatment of diabetic foot syndrome (DFS). The study found that prostanoids, such as iloprost and alprostadil, did not have a significant beneficial effect on major amputation, minor amputation, all-cause mortality, ulcer healing, pain, transcutaneous oxygen pressure (TcPO2), ankle-brachial index (ABI), quality of life, or peri-procedural complications. The authors concluded that the current evidence is not sufficient to support the extensive use of prostanoids in diabetic patients with CLTI, and further research is needed to determine their risk/benefit and cost/efficacy ratios. [Extracted from the article]